1-(2-(4-chlorophenoxy)-5-fluorophenyl)-N-methylethanamine | 289717-58-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(2-(4-chlorophenoxy)-5-fluorophenyl)-N-methylethanamine
• 英文别名: 1-[2-(4-chlorophenoxy)-5-fluorophenyl]-N-methylethanamine
• CAS: 289717-58-4
• 化学式: C₁₅H₁₅ClFNO
• 分子量: 279.73
• InChiKey: WJHPAIHCWWZGFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
  申请人：Pfizer Inc.

  公开号：US20020123490A1

  公开（公告）日：2002-09-05

  The present invention relates to a method of treating depression, obsessive compulsive disorder and psychosis in a mammal, including a human, by administering to the mammal an atypical antipsychotic in combination with an antidepressant agent with improvement in efficiency. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, an atypical antipsychotic, and an SRI.

  本发明涉及一种治疗哺乳动物，包括人类，的抑郁症、强迫症和精神病的方法，通过向哺乳动物投予一种非典型抗精神病药物与抗抑郁药物的组合，以提高效率。它还涉及含有一种药学上可接受的载体、一种非典型抗精神病药物和一种SRI的药物组合。
• Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
  申请人：Pfizer Inc.

  公开号：US20020147206A1

  公开（公告）日：2002-10-10

  The present invention relates to a method of treating Multiple Sclerosis, other demyelinating disorders and peripheral neuropathy in a mammal by administering to the mammal a neurotransmitter-inducing or precursor agent in combination with an (SRI) antidepressant or an anxiolytic agent with improvement in efficiency. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a neurotransmitter-inducing or precursor agent, and an SRI antidepressant or anxiolytic agent.

  本发明涉及一种治疗哺乳动物中多发性硬化症、其他脱髓鞘性疾病和外周神经病变的方法，该方法通过向哺乳动物投与一种神经递质诱导或前体药物，结合(SRI)抗抑郁药物或抗焦虑药物，以提高效率。还涉及含有药学上可接受的载体、神经递质诱导或前体药物以及SRI抗抑郁药物或抗焦虑药物的药物组合物。
• Combination treatment for alcoholism and alcohol dependence
  申请人：Pfizer Inc.

  公开号：US20030130322A1

  公开（公告）日：2003-07-10

  The present invention relates to a method of treating alcoholism or alcohol dependence in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with an opioid antagonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and an opioid antagonist.

  本发明涉及一种治疗哺乳动物（包括人类）酗酒或酒精依赖的方法，该方法包括给哺乳动物以单胺再摄取抑制剂与阿片受体拮抗剂的组合。本发明还涉及含有药学上可接受的载体、单胺再摄取抑制剂和阿片受体拮抗剂的制药组合物。
• Combination treatment for depression
  申请人：——

  公开号：US20020107244A1

  公开（公告）日：2002-08-08

  The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a 5-HT3 receptor antagonist in combination with an SRI antidepressant agent with improvement in sexual function and/or reduction in gastro-intestinal side effects. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5-HT3 receptor antagonist and an SRI antidepressant.

  本发明涉及一种治疗哺乳动物，包括人类的抑郁症或焦虑症的方法，通过给哺乳动物同时注射5-HT3受体拮抗剂和SRI抗抑郁剂来改善性功能和/或减少胃肠道副作用。它还涉及含有药用载体、5-HT3受体拮抗剂和SRI抗抑郁剂的制药组合物。
• Combination treatment for sleep disorders including sleep apnea
  申请人：Pfizer Inc.

  公开号：US20020183306A1

  公开（公告）日：2002-12-05

  The present invention relates to a method of treating sleep disorders including sleep apnea in a mammal, including a human, by administering to the mammal a 5HT1a antagonist or an alpha-2-adrenergic antagonist in combination with an SRI antidepressant agent with improvement in efficacy. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5HT1a antagonist or an alpha-2-adrenergic antagonist, and an SRI antidepressant agent.

  本发明涉及一种治疗哺乳动物（包括人类）的睡眠障碍，包括睡眠呼吸暂停的方法，通过给哺乳动物（包括人类）施用5HT1a拮抗剂或α-2肾上腺素受体拮抗剂与SRI抗抑郁药物的联合使用，以提高疗效。本发明还涉及含有药用载体、5HT1a拮抗剂或α-2肾上腺素受体拮抗剂和SRI抗抑郁药物的制药组合物。